Pharmaceutical Stocks Worth Watching - June 4th

Eli Lilly and Company, Blueprint Medicines, D-Wave Quantum, Regeneron Pharmaceuticals, and Merck & Co., Inc. are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture and market prescription drugs and therapies. Their market value is driven by factors such as clinical trial results, regulatory approvals, patent lifecycles and healthcare policy changes. Investors watch these stocks for potential growth from successful new treatments but also weigh risks like failed trials or patent expirations. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Shares of NYSE LLY traded up $17.72 during midday trading on Wednesday, hitting $768.50. The company had a trading volume of 1,573,320 shares, compared to its average volume of 3,631,054. The firm has a market capitalization of $728.34 billion, a price-to-earnings ratio of 65.63, a price-to-earnings-growth ratio of 1.40 and a beta of 0.48. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53. The business has a 50-day simple moving average of $773.82 and a two-hundred day simple moving average of $799.64. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00.

Read Our Latest Research Report on LLY

Blueprint Medicines (BPMC)

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.

Blueprint Medicines stock traded up $0.40 during mid-day trading on Wednesday, reaching $128.00. The company had a trading volume of 7,899,148 shares, compared to its average volume of 1,077,735. The stock's 50-day simple moving average is $93.17 and its 200-day simple moving average is $95.16. Blueprint Medicines has a 1 year low of $73.04 and a 1 year high of $128.15. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. The company has a market capitalization of $8.27 billion, a P/E ratio of -118.52 and a beta of 0.83.

Read Our Latest Research Report on BPMC

D-Wave Quantum (QBTS)

D-Wave Quantum Inc. develops and delivers quantum computing systems, software, and services worldwide. The company offers Advantage, a fifth-generation quantum computer; Ocean, a suite of open-source python tools; and Leap, a cloud-based service that provides real-time access to a live quantum computer, as well as access to Advantage, hybrid solvers, the Ocean software development kit, live code, demos, learning resources, and a vibrant developer community.

NYSE QBTS traded up $0.50 during trading hours on Wednesday, reaching $18.18. The company's stock had a trading volume of 39,684,734 shares, compared to its average volume of 43,920,266. The stock has a market cap of $5.31 billion, a PE ratio of -43.29 and a beta of 0.90. D-Wave Quantum has a fifty-two week low of $0.75 and a fifty-two week high of $19.77. The company's 50-day moving average is $9.96 and its two-hundred day moving average is $7.46.

Read Our Latest Research Report on QBTS

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

REGN traded down $1.33 during trading on Wednesday, hitting $486.53. The company's stock had a trading volume of 1,054,871 shares, compared to its average volume of 845,402. Regeneron Pharmaceuticals has a twelve month low of $481.58 and a twelve month high of $1,211.20. The stock has a market cap of $52.53 billion, a PE ratio of 12.71, a PEG ratio of 2.34 and a beta of 0.43. The firm's 50 day moving average price is $578.30 and its 200-day moving average price is $662.58. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95.

Read Our Latest Research Report on REGN

Merck & Co., Inc. (MRK)

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

NYSE MRK traded up $1.47 during trading hours on Wednesday, hitting $78.61. 6,418,178 shares of the company's stock were exchanged, compared to its average volume of 12,607,114. The business's 50 day moving average is $79.75 and its 200-day moving average is $90.29. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.15 and a current ratio of 1.36. Merck & Co., Inc. has a 12-month low of $73.31 and a 12-month high of $134.63. The firm has a market capitalization of $197.39 billion, a P/E ratio of 11.68, a price-to-earnings-growth ratio of 0.77 and a beta of 0.43.

Read Our Latest Research Report on MRK